Literature DB >> 12381345

CD8 T cells are sufficient to mediate allorecognition and allograft rejection.

Kate E Halamay1, Robert L Kirkman, Linhong Sun, Akira Yamada, Ruben C Fragoso, Koichi Shimizu, Richard N Mitchell, Dianne B McKay.   

Abstract

Different T cell subsets may play different roles in allorecognition and allograft rejection. It has been suggested that CD8 T cells can only initiate rejection with help from CD4 T cells. Since CD8 T cells may have different requirements for allorecognition and for costimulation, it is important to clarify the role of CD8 cells in rejection. We examined the role of CD8 cells in allorecognition using a TCR transgenic mouse transplantation model. In our study, CD8 cells were able to recognize alloantigens and reject allografts in the absence of help from CD4 T cells. Furthermore our study provides a model to study the mechanisms of CD8-mediated allograft rejection. It may be important in the future, to consider that CD8 T cells may need to be targeted independently of CD4 T cells in strategies used to prevent rejection and induce tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381345     DOI: 10.1016/s0008-8749(02)00530-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  CD8+ T cells mediate antibody-independent platelet clearance in mice.

Authors:  Connie M Arthur; Seema R Patel; H Cliff Sullivan; Annie M Winkler; Chris A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

2.  Absence of recipient C3aR1 signaling limits expansion and differentiation of alloreactive CD8+ T cell immunity and prolongs murine cardiac allograft survival.

Authors:  Douglas R Mathern; Julian K Horwitz; Peter S Heeger
Journal:  Am J Transplant       Date:  2019-01-14       Impact factor: 8.086

3.  Blockade of Notch ligand δ1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation.

Authors:  Leonardo V Riella; Takuya Ueno; Ibrahim Batal; Sacha A De Serres; Ribal Bassil; Wassim Elyaman; Hideo Yagita; José O Medina-Pestana; Anil Chandraker; Nader Najafian
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

Review 4.  Mechanisms of graft rejection after lung transplantation.

Authors:  Hsi-Min Hsiao; Davide Scozzi; Jason M Gauthier; Daniel Kreisel
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

5.  Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus.

Authors:  F Krenzien; M Quante; T Heinbokel; M Seyda; K Minami; H Uehara; H R C Biefer; J M Schuitenmaker; S Gabardi; K Splith; M Schmelzle; A K Petrides; H Azuma; J Pratschke; X C Li; A ElKhal; S G Tullius
Journal:  Am J Transplant       Date:  2016-11-21       Impact factor: 8.086

6.  Interferon regulatory factor 4 deficiency in CD8+ T cells abrogates terminal effector differentiation and promotes transplant acceptance.

Authors:  Dawei Zou; Jinfei Fu; Zhiyong Guo; Wenhao Chen
Journal:  Immunology       Date:  2020-10-12       Impact factor: 7.397

7.  Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.

Authors:  Alix K Berglund; Matthew B Fisher; Kristin A Cameron; Emma J Poole; Lauren V Schnabel
Journal:  Front Vet Sci       Date:  2017-06-12

Review 8.  Old game, new players: Linking classical theories to new trends in transplant immunology.

Authors:  Marina Burgos da Silva; Flavia Franco da Cunha; Fernanda Fernandes Terra; Niels Olsen Saraiva Camara
Journal:  World J Transplant       Date:  2017-02-24

9.  Identification of peripheral CD154+ T cells and HLA-DRB1 as biomarkers of acute cellular rejection in adult liver transplant recipients.

Authors:  F Boix; I Legaz; A Minhas; R Alfaro; V Jiménez-Coll; A Mrowiec; H Martínez-Banaclocha; J A Galián; C Botella; M R Moya-Quiles; F Sanchez-Bueno; R Robles; J de la Peña-Moral; P Ramirez; J A Pons; A Minguela; M Muro
Journal:  Clin Exp Immunol       Date:  2020-10-29       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.